Previous 10 | Next 10 |
New Drug Application (NDA) for sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter), is currently under Priority...
FDA Advisory Committee to review sulbactam-durlobactam for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalt...
2023-04-14 11:28:52 ET Summary Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one. IXJ: A global alternative to XLV. 10 stocks cheaper than their peers in April. This monthly art...
2023-03-16 23:28:11 ET Summary The latest financial results have been lackluster to put it mildly. Revenue and net income are down significantly. In spite of this, the shares are more expensive now than they were when I last reviewed the name. Everything in investing is relati...
2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review...
Innoviva press release ( NASDAQ: INVA ): Q4 EPS of -$0.98 may not be comparable to consensus of $0.25. Revenue of $65.8M (+439.3% Y/Y) beats by $6.95M . For further details see: InnovivaEPS of -$0.98, revenue of $65.8M beats by $6.95M
Royalties of $54.7 million in the fourth quarter of 2022 for RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® Net product sales of $14.6 million in the fourth quarter of 2022 for GIAPREZA ® and XERAVA ® $10...
Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC PR Newswire MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" ...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...